Arcturus Therapeutics (ARCT) Soars 7.17% on FDA Fast Track Designation

Arcturus Therapeutics (ARCT) surged 7.17% today, marking its second consecutive day of gains, with a total increase of 10.70% over the past two days. The share price reached its highest level since March 2025, with an intraday gain of 10.14%.

Arcturus Therapeutics recently received U.S. FDA Fast Track Designation for its STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1. This designation, noted in both July and April 2025 reports, signifies accelerated development and review processes, which could positively impact the company's stock price. The Fast Track Designation is a critical milestone for Arcturus, as it allows for more frequent interactions with the FDA and expedites the review process, potentially leading to faster market approval.

In addition to the Fast Track Designation, Arcturus Therapeutics announced their Q2 2025 earnings on August 4, 2025. This earnings report is crucial for current stock evaluations, as it provides insights into the company's financial performance and future prospects. Investors are closely monitoring these earnings to assess the company's growth trajectory and make informed investment decisions. The positive developments surrounding the STARR® mRNA Vaccine Candidate and the upcoming earnings report have contributed to the recent surge in Arcturus Therapeutics' stock price, reflecting investor confidence in the company's innovative mRNA technology and its potential to address global health challenges.